Quantcast
Last updated on April 24, 2014 at 13:44 EDT

Latest Hepatitis C virus Stories

2012-01-02 23:09:12

Mechanism explains how virus survives in the liver and how a new antiviral works Viral diseases are still one of the biggest challenges to medical science. Thanks to thousands of years of co-evolution with humans, their ability to harness the biology of their human hosts to survive and thrive makes them very difficult to target with medical treatment. Scientists at the University of North Carolina at Chapel Hill, working with colleagues from the University of Colorado, have shown for...

2011-12-15 16:35:03

Given that chimpanzees are so closely related to humans and share similar behavioral traits, the National Institutes of Health should allow their use as subjects in biomedical research only under stringent conditions, including the absence of any other suitable model and inability to ethically perform the research on people, says a new report from the Institute of Medicine and National Research Council.  In addition, use of these animals should be permissible only if forgoing their use...

2011-11-14 16:11:00

PRINCETON, N.J., Nov. 14, 2011 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS), a clinical stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections, today reported financial results and operational highlights for the fiscal year ended September 30, 2011. At fiscal year end Pharmasset held $166.5 million in cash and cash equivalents and used $21.7 million of our cash and cash equivalents during the fourth quarter of fiscal...

2011-11-07 10:00:00

SAN FRANCISCO and RIDGEFIELD, Conn., Nov. 7, 2011 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced results from a planned interim analysis of a Phase 2b study, SOUND-C2, that showed the combination of two oral direct acting hepatitis C virus (HCV) compounds - the protease inhibitor BI 201335 and the polymerase inhibitor BI 207127 with ribavirin (RBV) - was successful in reducing viral load below the lower limit of quantifiable levels at week 12 (viral response) in...

2011-11-05 08:05:00

SAN FRANCISCO, Nov. 5, 2011 /PRNewswire/ -- Tibotec Pharmaceuticals (Tibotec), one of the Janssen (Janssen) Pharmaceutical Companies, today will present results of the final analysis of PILLAR, a phase 2b study of the investigational hepatitis C virus (HCV) NS3/4A protease inhibitor TMC435 in treatment-naive patients with chronic genotype 1 HCV, as part of a late-breaker oral presentation at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in San...

2011-11-04 06:30:00

PRINCETON, N.J., Nov. 4, 2011 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS) today announced that it will webcast an investor event from the American Association for the Study of Liver Diseases (AASLD) on Sunday, November 6, 2011 starting at 6:30pm PT. During this webcast, management will review Pharmasset's progress on the programs that are the subject of presentations at AASLD. To download a slide presentation and access a simultaneous webcast of this event via the internet, log on to the...

2011-10-03 07:00:00

RIDGEFIELD, Conn., Oct. 3, 2011 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. announced today that new data from its hepatitis C virus (HCV) portfolio will be presented in scientific sessions at The Liver Meeting® 2011, the 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), taking place November 4 - November 8 in San Francisco, CA. The data will include results from a planned interim analysis of SOUND-C2, a Phase 2b study...

2011-09-26 15:00:00

CompassBiotech Making Drugs to Combat Major Human Diseases EDMONTON, Sept. 26, 2011 /PRNewswire/ - Compass (COBI:OB) is pleased to announce new research findings that it believes will alter the course of HCV vaccine development and other vaccines in general. Vaccine products continue to be the success story for pharmaceutical companies, with the world market for preventative vaccines in 2010 being $ 28 billion as compared to $26 billion in 2009, $24 billion in 2008 and $18.5...

2011-09-20 07:37:00

SANTA CRUZ, Calif., Sept. 20, 2011 /PRNewswire/ -- SomaGenics, Inc., a biotechnology company specializing in RNA-based technologies, presented exciting data on the efficacy of RNA interference (RNAi) therapeutics against Hepatitis C virus (HCV) based on the company's sshRNA platform. SomaGenics, along with its collaborators at Tekmira Pharmaceuticals and Roche, presented the results in a poster entitled "Synthetic Short shRNAs are Potent Inhibitors of Hepatitis C Virus in HCV-Infected...

2011-09-19 05:25:41

(Ivanhoe Newswire)--- According to the CDC, Hepatitis C is the most common chronic blood borne infection in the United States affecting more than 3.2 million people.  But, a new drug has been found to significantly increase the cure rates for those infected. Hepatitis C virus (HCV) is a disease that can cause severe liver damage, joint pain and even damage to the nervous system and brain. HCV genotype 1 is the most common form of the virus and also the most difficult to treat. ...


Latest Hepatitis C virus Reference Libraries

11_c18ff18c314281da28f1d18fa4357602
2011-01-20 19:28:48

Hepatitis E virus is an infective organism. The viral particles are 27 to 34 nanometers in diameter. They are non-enveloped and contain a single-strand of positive-sense RNA which is approximately 7300 bases in length. The virus was first visualized in 1983 and molecularly cloned in 1990. Previously it was classified in the family Caliciviridae. Its genome more closely resembles the rubella virus and is now classified as the only member of the genus Hepevirus which has not yet been...

11_9e88d15808b8ecc3fcbbdfcf4ae75786
2011-01-20 19:23:30

Hepatitis C virus (HCV) is an enveloped, positive-sense single-stranded RNA virus of the family Flaviviridae. It consists of a core of genetic material surrounded by an icosahedra protective shell of protein. The genome consists of a single open reading frame that is 9600 nucleotide bases long. HCV replication takes several steps. It primarily replicates in the hepatocytes of the liver. It can also reproduce in peripheral blood mononuclear cells. There is a wide variety of genotypes and...

More Articles (2 articles) »